Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Other Working Capital Changes (2019 - 2025)

Harmony Biosciences Holdings' Other Working Capital Changes history spans 7 years, with the latest figure at -$24.8 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 1248.07% year-over-year to -$24.8 million; the TTM value through Dec 2025 reached -$31.8 million, down 1156.75%, while the annual FY2025 figure was -$31.8 million, 1156.75% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$24.8 million at Harmony Biosciences Holdings, down from -$12.5 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $7.7 million in Q4 2022 and bottomed at -$24.8 million in Q4 2025.
  • The 5-year median for Other Working Capital Changes is -$2000.0 (2021), against an average of -$1.1 million.
  • The largest annual shift saw Other Working Capital Changes plummeted 47640.0% in 2022 before it surged 398500.0% in 2023.
  • A 5-year view of Other Working Capital Changes shows it stood at -$162000.0 in 2021, then soared by 4852.47% to $7.7 million in 2022, then tumbled by 123.81% to -$1.8 million in 2023, then fell by 0.55% to -$1.8 million in 2024, then crashed by 1248.07% to -$24.8 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Other Working Capital Changes are -$24.8 million (Q4 2025), -$12.5 million (Q3 2025), and $3.6 million (Q2 2025).